Macular degeneration, or age-related macular degeneration (AMD), is a leading cause of vision loss in Americans 60 and older. It is a disease that destroys your sharp, central vision.
Programs + Services
Ophthalmology (New England Eye Center) at Tufts Medical Center in Boston specializes in the testing and treatment of all types of eye diseases and visual problems.
More information about programs and services
Research + Clinical Trials
Microperimetry allows for precise structure-function correlation studies to be performed on the retina. By creating a map of retinal sensitivity and overlaying it onto images of the retina, structure-function correlation can be determined. Already used in common retinal diseases like diabetic retinopathy, microperimetry has proven useful as a diagnostic tool. Studies have shown early changes in retinal sensitivity associated with disease even before there are major clinically apparent changes in the eye. This suggests that there may be subtle changes to eye structure and function before vision is noticeably impaired—better understanding these changes could provide rationale for earlier intervention to prevent deterioration in patient vision. This study seeks to assess possible structural and functional changes over the course of the disease progression in a variety of retinal disorders by using microperimetry in combination with optical coherence tomography imaging. This could allow for
earlier detection of diseases, provide rationale for earlier intervention, and provide a means of tracking and managing disease progression.
More information about research and clinical trials
This study will evaluate the efficacy, safety, and pharmacokinetics of ranibizumab delivered with the PDS Implant compared with ranibizumab delivered as a monthly intravitreal injection in patients with neovascular age-related macular degeneration (nAMD).
More information about research and clinical trials
This study is being done to see if some eye tests could be useful in finding the natural changes that happen over time in the retina (the back part of the eye) of patients with GA secondary to AMD.
More information about research and clinical trials
